Feasibility and Performance Evaluation for INVSENSOR00024
NCT ID: NCT03570255
Last Updated: 2020-02-20
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
28 participants
INTERVENTIONAL
2018-06-25
2019-11-08
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Feasibility and Performance Evaluation of INVSENSOR00024
NCT03831282
Desaturation Validation of INVSENSOR00006
NCT03435211
Desaturation Validation of INVSENSOR00012
NCT03435224
Desaturation Validation of INVSENSOR00031
NCT03783780
Desaturation Validation of INVSENSOR00039
NCT04112784
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
RD SET Neo SpO2
All subjects enrolled in the study will receive the investigational sensor (RD SET Neo SpO2) for evaluation of SpO2.
RD SET Neo SpO2
All subjects are enrolled in the experimental group and receive the RD SET Neo SpO2 sensor.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
RD SET Neo SpO2
All subjects are enrolled in the experimental group and receive the RD SET Neo SpO2 sensor.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Weight \<3kg
* Subjects admitted with standard of care (SOC) arterial blood sampling line already in place
Exclusion Criteria
* Subjects with abnormalities at the planned application sites that would interfere with system measurements
* Subjects with known allergic reactions to foam/rubber products and adhesive tape
* Deformities of limbs, absence of feet, sever edema, and other at the discretion of the Principal Investigator
1 Month
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Masimo Corporation
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Stanford University Medical Center
Stanford, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HAMM0002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.